Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents

@inproceedings{Tourneau2012EfficiencyON,
  title={Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents},
  author={Christophe Le Tourneau and Hui Kong Gan and Albiruni Ryan Abdul Razak and Xavier Paoletti},
  booktitle={PloS one},
  year={2012}
}
BACKGROUND Statistical simulations have consistently demonstrated that new dose-escalation designs such as accelerated titration design (ATD) and continual reassessment method (CRM)-type designs outperform the standard "3+3" design in phase I cancer clinical trials. METHODS We evaluated the actual efficiency of different dose escalation methods employed in first-in-human phase I clinical trials of targeted agents administered as single agents published over the last decade. RESULTS Forty… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 14 references

The continual reassessment method (CRM) for dose escalation in phase I trials in San Antonio does not result in more rapid study completion

  • SG Eckhardt, LL Siu, G Clark, C DeMoor, DD Von Hoff
  • Proc Am Soc Clin Oncol
  • 1999
Highly Influential
5 Excerpts

Dose escalation methodology in phase I clinical trials: a comparison of the modified continual reassessment method (MCRM) and a traditional method. Experience with the multitargeted antifolate (MTA)

  • J Walling, PH Zervos, S McCarthy, DA Rinaldi, A McDonald
  • Proc Am Soc Clin Oncol ( abstract # 733 )
  • 1997
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…